Tom 15, Nr 3 (2020)
Opis przypadku
Opublikowany online: 2020-10-23
Wyświetlenia strony
1798
Wyświetlenia/pobrania artykułu
890
Zastosowanie skali The Dutch Lipid Clinic Network w diagnostyce hipercholesterolemii rodzinnej i dalsze implikacje kliniczne w erze inhibitorów PCSK9
1, 1, 1
DOI: 10.5603/FC.2020.0033
Folia Cardiologica 2020;15(3):258-264.
Streszczenie
W artykule opisano przypadek 64-letniego pacjenta z wieloletnim wywiadem choroby wieńcowej, po licznych incydentach wieńcowych i przezskórnej interwencji wieńcowej, u którego późno zdiagnozowano hipercholesterolemię rodzinną (FH). Na podstawie przypadku klinicznego przedstawiono aktualne możliwości diagnostyczne i istotność wczesnego rozpoznania FH oraz nowoczesną terapię hipolipemizującą z wykorzystaniem inhibitorów PCSK9.
Słowa kluczowe: hipercholesterolemia rodzinnainhibitory PCSK9skala the Dutch Lipid Clinic Network
Referencje
- Bandosz P, O'Flaherty M, Drygas W, et al. Decline in mortality from coronary heart disease in Poland after socioeconomic transformation: modelling study. BMJ. 2012; 344: d8136.
- Szymański FM, Barylski M, Cybulska B, et al. Recommendation for the management of dyslipidemia in Poland — Third Declaration of Sopot. Interdisciplinary Expert Position Statement endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy. Cardiol J. 2018; 25(6): 655–665.
- Mach F, Baigent C, Catapano AL, et al. ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41(1): 111–188.
- Knuuti J, Wijns W, Saraste A, et al. ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020; 41(3): 407–477.
- Sabatine MS, Giugliano RP, Keech AC, et al. FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017; 376(18): 1713–1722.
- Schwartz GG, Steg PhG, Szarek M, et al. ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018; 379(22): 2097–2107.
- Navarese EP, Kolodziejczak M, Kereiakes DJ, et al. Proprotein convertase subtilisin/kexin type 9 monoclonal antibodies for acute coronary syndrome: a narrative review. Ann Intern Med. 2016; 164(9): 600–607.
- Raal FJ, Stein EA, Dufour R, et al. RUTHERFORD-2 Investigators. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015; 385(9965): 331–340.
- Kastelein JJP, Robinson JG, Farnier M, et al. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies. Cardiovasc Drugs Ther. 2014; 28(3): 281–289.
- https://indeks.mp.pl/leki/desc.php?id=15503 [ewolokumab]; https://indeks.mp.pl/leki/desc.php?id=17057 [alirokumab] (November 11, 2019).
- Nordestgaard BG, Chapman MJ, Humphries SE, et al. European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013; 34(45): 3478–90a.
- hipercholesterolemia.pl (November 11, 2019).
- https://www.gov.pl/web/zdrowie/choroby-nieonkologiczne (November 11, 2019).
- Moriarty PM, Jacobson TA, Bruckert E, et al. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. J Clin Lipidol. 2014; 8(6): 554–561.
- Robinson JG, Colhoun HM, Bays HE, et al. Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS Studies. Clin Cardiol. 2014; 37(10): 597–604.
- Bandyopadhyay D, Ashish K, Hajra A, et al. Cardiovascular outcomes of PCSK9 inhibitors: with special emphasis on its effect beyond LDL-cholesterol lowering. J Lipids. 2018; 2018: 3179201.
